Comparison of the Efficacy and Side Effects of IFN Beta 1–a (Rebif) and a Biosimilar Product (Recigen) in Patients with Multiple Sclerosis

Document Type : Original Article (s)

Authors

1 Professor, Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Resident , Department of Neurology, School of Medicine And Student Research committee, Isfahan University of Medical Sciences, Isfahan, Iran

3 Research Coordinator, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Medical Statistics consultant, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Multiple sclerosis, or MS, is a chronic demyelinating disorder of the central nervous system affecting over 400,000 people in the US and 2 million individuals worldwide. MS often results in severe disability. Unfortunately, the etiology of multiple sclerosis is unknown and there is no known cure for the disease, and treatments are modest at best. Although, many drugs were found and produced for the treatment of MS, such as Rebif, Avonex and etcetera, these drugs are often very expensive. Recigen, which is an Iranian biosimilar product, is the same as Rebif. In this study we compared the efficacy and side effects of Rebif and Recigen in the treatment of MS.Methods: In a randomized clinical trial 44 patients with EDSS between 0-4 were enrolled and divided into two groups. Of these patients 36 were followed up to the end of the study. The first group was treated by Rebif and the second was treated by Recigen for 24 monts. During the study, EDSS, Relapses drug complications, active plaques and plaque volume were studied and recorded in a special form. Finally all data were entered into the computer and analyzed by SPSS software. The chi-square, student’s t-test and repeated measures ANOVA were used for data analysis.Findings: According to the results of this study the trend of EDSS between two groups was the same, and there was no statistical difference between the two groups (P = 0.13). Moreover, no statistical difference was seen between the two groups in relapse number (P = 0.6). In addition, the plaque volume in both groups decreased, but there was no difference between the two groups. Conclusion: The results of this study showed that Recigen is as effective as rebif and has no significant side effects.

Keywords

References

  1. Mouzat L. Principal nervous disorders. Rev Infirm 2006; (121): 17-21. [In French]
  2. Botzel K, Straube A. Neurology: current advances 2006. Dtsch Med Wochenschr 2006; 131(25-26): 1481-4. [In German]
  3. Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vecsei L, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006; 13(7): 700-22.
  4. Miszkiel KA, Thompson AJ, Plant GT, Miller DH. The epidemiology of multiple sclerosis. Am J Epidemiol 2006; 14(4): 363-9.
  5. Rudick RA, Cohen JA, Weinstock-Guttman B, Kinkel RP, Ransohoff RM. Management of multiple sclerosis. N Engl J Med 1997; 337(22): 1604-11.
  6. Stuifbergen AK, Blozis SA, Harrison TC, Becker HA. Exercise, functional limitations, and quality of life: A longitudinal study of persons with multiple sclerosis. Arch Phys Med Rehabil 2006; 87(7): 935-43.
  7. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993; 43(4): 655-61.
  8. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39(3): 285-94.
  9. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352(9139): 1498-504.
  10. Bradley WG, Daroff RB, Fenichel GM, Jankovic J. Bradley's Neurology in Clinical Practice. 6th ed. Elsevier; 2008. p. 1606-7.
  11. Stachowiak J. Rebif for Multiple Sclerosis Treatment. [cited 2009 Jul 21]. Available from: http://ms.about.com/od/treatments/a/rebif.htm.
  12. Stuart WH, Cohan S, Richert JR, Achiron A. Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis. Neurology 2004; 63(11 Suppl 5): S19-S27.
  13. Neilley LK, Goodin DS, Goodkin DE, Hauser SL. Side effect profile of interferon beta-1b in MS: results of an open label trial. Neurology 1996; 46(2): 552-4.
  14. Hemmer B, Nessler S, Zhou D, Kieseier B, Hartung HP. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol 2006; 2(4): 201-11.
  15. Al.sabbgh A. Neutralizing antibodies in MS therapy: reviewing the rebif experience. Neurology. 2007. 69(7): 1210-15.
Journal of Isfahan Medical School
Volume 29, Issue 162 - Serial Number 162
September and October 2012
Pages 1964-1974

Files

History

  • Receive Date: 15 June 2011
  • Revise Date: 23 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics